Table 1.
Demographic and Clinical Characteristics of Study Group
|
Variable |
Mean ± Standard Deviation (Range) or Median (Range) |
|---|---|
| n | 11 |
| Age, y | 30.6 ± 8.5 (21–48) |
| BMI, kg/m2 | 28.5 ± 7.4 (20.3–39.3) |
| Duration of T therapy, wk | 119 ± 126 (8–434) |
| Duration of SC T therapy, wk | 47.6 ± 19.3 (8–72) |
| SC T dose, mg | 75 (50–100) |
| Pretherapy hormone levelsa | |
| Total testosterone | 52.8 ± 26.3 (27–103, n = 8) |
| Free testosterone | 3.7 ± 3.7 (0.6–11.0, n = 6) |
| Prestudy hormone levelsb | |
| Total testosterone, ng/dL | 671 ± 238 (340–1184) |
| Free testosterone, pg/mL | 119 ± 49 (41–199) |
| Estradiol, pg/mL | 39.0 ± 18.4 (14–68) |
Abbreviation: T, testosterone.
a
Prior to initiation of testosterone therapy (performed at LabCorp).
b
Most recent serum testosterone measurement while on therapy and prior to the study week (performed at LabCorp).